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Background: There is an increasing use of ayahuasca for recreational purposes. Furthermore, there is a growing
evidence for the antidepressant properties of its components. However, there are no reports on the effects of this
substance in the psychiatric setting. Harmaline, one of the main components of ayahuasca, is a selective and
reversible MAO-A inhibitor and a serotonin reuptake inhibitor.
Case report: We present the case of a man with bipolar disorder who had a manic episode after an ayahuasca
consumption ritual. This patient had had at least one hypomanic episode in the past and is currently depressed.
We discuss the diagnostic repercussion of this manic episode.
Conclusion: There is lack of specificity in the diagnosis of substance-induced mental disorder. The knowledge of
the pharmacodynamic properties of ayahuasca consumption allows a more physiopathological approach to the
diagnosis of the patient.
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Ayahuasca is a psychotropic, hallucinogenic beverage,
composed of a mixture of Amazonian plants. It is usu-
ally consumed as an infusion with Banisteriopsis caapi
and Psychotria viridis (Guimaraes dos Santos 2010). The
main components of B. caapi are β-carbolines - harmine
and tetrahydroharmine - and to a lesser extent harma-
line, harmol, and harmalol, while P. viridis contains a
tryptamine, N,N-dimethyltryptamine (DMT), and a 5HT
2A agonist (Guimaraes dos Santos 2010; Callaway et al.
2005; McKenna et al. 1998). DMT, from P. viridis species,
is the psychoactive substance of ayahuasca (Guimaraes
dos Santos 2010). DMT is orally inactive due to intestinal
MAO-A metabolism. Harmine, harmaline, and tetrahy-
droharmine are reversible, competitive, selective inhibitors
of MAO-A (Guimaraes dos Santos 2010), with almost no
effect on MAO-B (Herraiz 2010). When DMT is orally
administered, it is peripherally inactivated by MAO-A
(Riba et al. 2012). Nevertheless, when it is combined
with a peripheral MAO-A inhibitor (like harmine), its* Correspondence: alejandroszm@gmail.com
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reproduction in any medium, provided the origoral biodisponibility increases, this interaction being the
base of ayahuasca psychotropic effect (McKenna 2004).
Case presentation
We present the case of a 30-year-old Argentinian man,
single and currently unemployed, who lives with his
mother. He arrived at our emergency room in order to
continue treatment after being discharged from a hospital
in Brazil. It was in there where he was admitted due to an
acute psychotic episode after being involved in a 4-day rit-
ual of ayahuasca consumption.
The patient had traveled to Brazil 3 months before in
order to learn about South American tribes. In this con-
text, he was offered to take part in an ayahuasca consump-
tion ritual. Two days after the last consumption, he began
having mystical and paranoid delusional ideas, auditory
hallucinations, racing thoughts, disorganized behavior,
elevated energy, and euphoria. The psychotic symptoms
were consistent with his euphoric mood. He was taken to
a psychiatric hospital where he received risperidone 2 mg/
day and clonazepam 2 mg/day. After a month of being
admitted, he was asymptomatic and was discharged with
the same medication and traveled back to Argentina to
continue his treatment. According to his mother (and by
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toms previously described. He maintained a coherent
speech and slept 8 h per day.
The patient is the youngest brother in a family of
middle socioeconomic status. He had a eutocic birth and
reached developmental milestones at appropriate times.
When he was 6 years old, he was enrolled in primary
school where he developed asthma, enuresis, and night
terrors. He was a sociable child and reports no substance
abuse disorder. He graduated from high school and
started a course of business management. His family back-
ground revealed that his father suffered bipolar disorder
type I.
Two weeks before the journey to Brazil, the patient
presented a period of increased energy and goal-directed
activity, sleep disorder, pressured speech, increased self-
esteem, and running thoughts that lasted for 10 days,
compatible with a hypomanic episode. He states that he
had experienced this kind of episodes several times in
the past. There was no previous history of manic or de-
pressive episodes.
As per an actual mental state examination in our hos-
pital, the amount and speed of speech were diminished,
and his affect was depressed. His thought content pre-
sented ideas of hopelessness and ruin. He had no delu-
sions or hallucinations. He showed marked anhedonia,
apathy, and clinophilia. His sleep and appetite were nor-
mal. This depressive episode started immediately after
the remission of the psychotic episode described above.
Discussion
We have presented a case of a patient with a previous
history of hypomanic episodes and a first-degree family
history of bipolar disorder. In the context of ayahuasca
consumption, this patient developed a manic episode
with psychotic features, which leads us to wonder about
its etiology.
Substance-induced mental disorders are diagnosed ac-
cording to DSM 5 when the characteristic symptoms of
the disorder appear during or up to 1 month after the
consumption of a substance, if there is no data to justify
a primary disorder (i.e., symptoms preceding the use of
the substance) (American Psychiatric Association 2013).
After conducting a review, it is seen that in most cases,
the clinical features of ayahuasca-induced psychotic
disorder are similar: sensory perception disturbances
(the most frequent visual hallucinations), elevated body
temperature, cardiovascular events (bradycardia, hypoten-
sion), psychomotor agitation, ataxia, tremors, and vomit-
ing (Frison et al. 2008; Mahmoudian et al. 2002; Ben Salah
et al. 1986).
The presence of preexisting hypomanic episodes, the
presence of a positive family history of bipolar disorder,
the absence of associated neurovegetative symptoms,and the fact that ayahuasca psychotic episodes are rare
and transient during consumption do not support a
diagnosis of either psychotic or bipolar disorder induced
by ayahuasca nor ayahuasca intoxication. In addition, a
revision made by Gable and colleagues (Gable 2007)
reports that psychotic episodes induced by ayahuasca com-
ponents are rare (under 1%) and resolve spontaneously in
a few hours.
For some time, data postulating the antidepressant
action of one component of ayahuasca, harmine, began
to appear. This component may have inhibitory actions
on serotonin reuptake and agonism of the serotonin 1A
receptor. It also acts as a reversible inhibitor of MAO-A
enzyme (Guimaraes dos Santos 2010; Ng et al. 2008;
Glennon et al. 2000; Herraiz et al. 2010).
In summary, we believe that this patient had an
antidepressant-induced mania due to excessively pro-
longed use of a substance with antidepressant properties
and his bipolar disorder. There are studies that suggest a
4.58% (Tondo et al. 2010) to 15% (Pickar 1982) risk of
switch to mania in bipolar patients treated with MAO
inhibitors.
According to DSM 5, ‘a manic episode that emerges
during antidepressant treatment but persists beyond the
physiological effect of treatment is sufficient evidence of
manic episode and therefore a bipolar disorder type I’
(American Psychiatric Association 2013); given that for
high doses of β-carbolines the half-life is 1 to 5 h (Riba
et al. 2003), we believe this is the case of the patient
presented.
Conclusions
In our patient, manic symptoms were caused by the
antidepressant effect of the substance and by his bipolar
disorder diagnosis. The reported case illustrates a lack of
specificity in the diagnosis of a substance-induced psych-
otic episode and suggests a decreased threshold to manic
episodes in bipolar patients by any compound with anti-
depressant action. Additionally, it emphasizes the utility
of DSM 5 modification of the antidepressant-induced
manic symptoms as exclusion criteria for a bipolar dis-
order diagnosis.
Finally, this case describes another mechanism of tox-
icity for this substance in bipolar patients and accentu-
ates the need for caution in the psychiatric setting.
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